Combination Treatment of Rosuvastatin or Atorvastatin, with Regular Exercise Improves Arterial Wall Stiffness in Patients with Coronary Artery Disease

Kensuke Toyama1,2,3, Seigo Sugiyama1*, Hideki Oka3, Yuri Iwasaki4, Hitoshi Sumida5, Tomoko Tanaka6, Shinji Tayama3,6, Hideaki Jinnouchi6, Hisao Ogawa1

1 Faculty of Life Science, Department of Cardiovascular Medicine, Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan, 2 Research Fellowship of the Japan Society for the Promotion of Science, Tokyo, Japan, 3 Division of Cardiology, Health Insurance Hitoyoshi General Hospital, Kumamoto, Japan, 4 Clinical Research Center, Health Insurance Hitoyoshi General Hospital, Kumamoto, Japan, 5 Division of Cardiology, Kumamoto Central Hospital, Kumamoto, Japan, 6 Division of Preventive Cardiology, Department of Cardiovascular Medicine, Kumamoto University Hospital, Kumamoto, Japan

Abstract

Objective: Statin- and exercise-therapy are both clinically beneficial by preventing cardiovascular events in patients with coronary artery disease (CAD). However, there is no information on the vascular effects of the combination of statins and exercise on arterial wall stiffness in CAD patients.

Methods: The present study is a sub-analysis of PRESET study that determined the effects of 20-week treatment with statins (rosuvastatin, n = 14, atorvastatin, n = 14) combined with regular exercise on arterial wall stiffness assessed by measurement of brachial and ankle pulse wave velocity (baPWV) in CAD patients.

Results: The combination of statins and regular exercise significantly improved exercise capacity, lipid profile, including low- and high-density lipoprotein cholesterol, and high-sensitivity C-reactive protein (hs-CRP), baPWV (baseline: 1747 ± 355, at 20 weeks of treatment: 1627 ± 271 cm/s, p = 0.008), and basophil count (baseline: 42 ± 32, 20 weeks: 26 ± 15 cells/μL, p = 0.007), but had no effect on blood pressure (baseline: 125 ± 22, 20 weeks: 121 ± 16 mmHg). Changes in baPWV correlated significantly with changes in basophil count (r = 0.488, p = 0.008), but not with age, lipids profile, exercise capacity, or hs-CRP.

Conclusion: In CAD patients, the combination treatment with statins and exercise resulted in significant amelioration of arterial wall stiffness, at least in part, through reduction of circulating basophils.

Introduction

The importance of exercise for patients with coronary artery disease (CAD) has been demonstrated [1,2]. Furthermore, the use of 3-hydroxy-3-methylglutaryl coenzyme A reductase (HMG-CoA reductase; statin) is effective in reducing cardiovascular events [3]. Thus, the combination of statin and regular exercise should improve quality of life and prognosis, and should be recommended for all CAD patients. We reported previously in the study of the Japan Society for the Promotion of Science, Tokyo, Japan, 3 Division of Cardiology, Health Insurance Hitoyoshi General Hospital, Kumamoto, Japan, 4 Clinical Research Center, Health Insurance Hitoyoshi General Hospital, Kumamoto, Japan, 5 Division of Cardiology, Kumamoto Central Hospital, Kumamoto, Japan, 6 Division of Preventive Cardiology, Department of Cardiovascular Medicine, Kumamoto University Hospital, Kumamoto, Japan

PWV is considered a potentially useful therapeutic strategy in the overall management of patients with cardiovascular disease. However, there is little or no information on the synergistic effects of the combination of statin treatment and exercise on arterial wall stiffness and inflammatory markers in patients with CAD. The aim of the present study was to determine the effects of statin therapy (rosuvastatin or atorvastatin) combined with regular exercise on arterial wall stiffness, and to clarify the relationship between inflammatory markers and arterial wall stiffness in patients with CAD.

Materials and Methods

Study Design

The design of this study (identification number UMIN00002799) has already been described in detail [4]. After dividing 28 Japanese CAD patients with a history of myocardial
infarction, angina pectoris or 50% or more stenosis in at least one major coronary artery into an atorvastatin (n = 14) and a rosuvastatin (n = 14) group at random, the patients performed weekly in-hospital aerobic training for half an hour on a bicycle ergometer based on their anaerobic threshold for 20 weeks. A well-trained registered exercise rehabilitation instructor instructed all patients on carrying out home training for half an hour by walking with Borg Scale 12–13 during the study. Atorvastatin was administered at doses from 10 to 40 mg/day and rosuvastatin from 2.5 to 20 mg/day, without any other lipid-lowering drug, to lower low-density lipoprotein cholesterol (LDL-C) levels below 100 mg/dL, according to the guidelines of the Japan Atherosclerosis Society [7]. The protocol of the PRESET study was approved by the Institutional Review Board of Health Insurance Hitoyoshi General Hospital in Kumamoto, Japan and a signed consent form was obtained from each subject.

Measurement of Brachial and Ankle Pulse Wave Velocity

The patient was examined in the morning following an overnight fast at the time of enrollment and at end of the study. The brachial and ankle PWV (baPWV) was measured after a 10 min-rest using an automatic waveform analyzer (form PWV/ABI, Colin, Komaki, Japan) while the subject was in the supine position. As described previously [8], we analyzed the higher baPWV level measured on either side of each patient at the beginning of the study, and repeated the analysis on the same side in each patient during the study.

Leucocytes Count and High-Sensitivity C-Reactive Protein (hs-CRP) Assay

As reported previously [4], venous blood samples were collected in the morning before the exercise test following an overnight fast. Total leukocyte and differential leukocyte counts were determined automatically using a XE-2100 (Sysmex Corporation, Japan). The hs-CRP level was measured by nephelometry with BNII (Siemens, Berlin, Germany) at the Japan SRL Laboratory (Tokyo).

Statistical Analysis

The present study is a sub-analysis of the PRESET study which has been conducted to investigate the different effects of atorvastatin or rosuvastatin combined with regular exercise on the serum ubiquinol levels. As mentioned previously [4], power analysis indicated that an enrollment of 22 patients was required to detect a mean decrease in ubiquinol levels of 350 nmol/L in atorvastatin group and 0 nmol/L in rosuvastatin group, with a power of 80% and a two-sided alpha of 0.05.

To compare the baseline characteristics of the two groups, data were analyzed by the Student’s t-test or Mann-Whitney U test, as appropriate. A paired Student’s t-test or Wilcoxon test was performed to analyze the effect of 20-week treatment. The Pearson correlation test was used to analyze the correlation between changes in baPWV and other parameters. Hazard ratios, 95% confidence intervals (95%CI), and levels of statistical significance (p values) were calculated. Data were expressed as mean ± standard deviation (SD) or median values, and p<0.05 was considered statistically significant. All statistical analyses were performed using the Statistical Package for Social Sciences, version 11.0J (SPSS Inc., Chicago, IL).

Results

Patient Characteristics

Table 1 summarizes the baseline characteristics of the patients in the PRESET study. As mentioned previously [4], cardiopulmonary function measured by peak oxygen uptake (Peak VO2) significantly improved after the combination treatment of statins plus regular exercise in the entire group (Figure 1A).

Changes in Blood Pressure and Arterial Wall Stiffness

Systolic and diastolic blood pressure in all patients did not change significantly during the study (125±22 mm Hg to 121±16 mm Hg, p = 0.227, Figure 1B). Mean arterial pressures did not change either after treatment (91±12 mm Hg to 89±10 mm Hg, p = 0.329). As shown in Figure 1C, the combination treatment significantly reduced the baPWV of the entire group. Changes in baPWV did not correlate significantly with changes in mean arterial pressures (r = 0.243, p = 0.209).

Changes in Inflammatory Factors, Metabolic Parameters, and Ubiquinol

The combination treatment significantly reduced plasma basophil count and serum hs-CRP level (Figure 1D, Table 2), significantly increased HDL-C and significantly reduced total cholesterol (T-Chol), triglyceride, LDL-C, non-HDL, and ubiquinol for the whole group (Table 2). However, the same treatment had no effect on total leukocytes, differential leukocyte counts; neutrophil, lymphocyte, monocyte, eosinophil counts, fasting blood glucose and hemoglobin A1c (HbA1c) during the study (Table 2).

Relationship Between Arterial Wall Stiffness and Inflammatory Factors

Changes in basophil count correlated significantly with the changes in baPWV in all patients (Figure 2A). There were not significant correlations between changes in total leukocytes, neutrophil, lymphocyte, monocyte, eosinophil, and hs-CRP and changes in baPWV (Figures 2B-F and 3A).

Table 1. Patients’ Characteristics.

| n     | 28 |
|-------|----|
| Age (years) | 67±11 |
| Male Gender, n (%) | 21 (75%) |
| Body Mass Index (kg/m²) | 24.5±3.0 |
| Left Ventricular Ejection Fraction (%) | 60.5±7.9 |
| E/A Ratio | 0.9±0.3 |
| Hypertension, n (%) | 25 (89%) |
| Diabetes, n (%) | 14 (50%) |
| Dyslipidemia, n (%) | 23 (82%) |
| Smoking, n (%) | 8 (29%) |
| Myocardial Infarction, n (%) | 9 (32%) |
| Angina Pectoris, n (%) | 14 (50%) |
| Multi Vessel Disease, n (%) | 14 (50%) |
| Aspirin, n (%) | 26 (93%) |
| Angiotensin Converting Enzyme Inhibitors, n (%) | 10 (36%) |
| Angiotensin II Receptor Blockers, n (%) | 14 (50%) |
| Calcium Channel Blockers, n (%) | 14 (50%) |

Data are mean ± SD or percentage of patients. doi:10.1371/journal.pone.0041369.t001
Figure 1. Effect of Combination Treatment on Arterial Wall Stiffness and Plasma Basophil. Effects of treatment on (A) peak oxygen uptake (peak VO₂), (B) blood pressure, (C) arterial wall stiffness measured by brachial and ankle pulse wave velocity (baPWV) and (D) plasma basophil count using data of all patients (n = 28). Data are mean ± SD. SBP, systolic blood pressure; DBP, diastolic blood pressure.
doi:10.1371/journal.pone.0041369.g001

Table 2. Effects of Statin-Exercise Treatment on Various Parameters.

| Parameter                                      | All (n = 28) | Baseline   | 20 weeks  | p value |
|------------------------------------------------|--------------|------------|-----------|---------|
| Total Cholesterol (mg/dL)                      | 202±35       | 147±24     |           | <0.001  |
| High-Density Lipoprotein Cholesterol (mg/dL)   | 46±14        | 54±14      |           | <0.001  |
| Triglyceride (mg/dL)                           | 133±47       | 90±42      |           | <0.001  |
| Low-Density Lipoprotein Cholesterol (mg/dL)    | 129±31       | 75±14      |           | <0.001  |
| Non-High-Density Lipoprotein Cholesterol (mg/dL)| 156±35      | 93±18      |           | <0.001  |
| Ubiquinol (nmol/L)                             | 706±233      | 608±264    |           | 0.016   |
| Fasting Blood Glucose (mg/dL)                  | 104±19       | 101±15     |           | 0.324   |
| Hemoglobin A1c (%)                             | 5.8±0.8      | 5.6±0.6    |           | 0.231   |
| Total Leukocyte Count (cells/µL)               | 5225±1472    | 4980±1263  |           | 0.286   |
| - Neutrophil (cells/µL)                        | 3217±1048    | 2968±1007  |           | 0.211   |
| - Lymphocyte (cells/µL)                        | 1465±449     | 1511±439   |           | 0.465   |
| - Monocyte (cells/µL)                          | 303±116      | 278±102    |           | 0.144   |
| - Eosinophil (cells/µL)                        | 199±107      | 198±151    |           | 0.940   |
| High-Sensitivity C-Reactive Protein (ng/mL)    | 1430 (264–2478) | 307 (146–623) |  | <0.001  |

Data are mean ± SD or median values (25th to 75th percentile range).
doi:10.1371/journal.pone.0041369.t002
Relationship Between Arterial Wall Stiffness and Other Parameters

Changes in baPWV did not correlate significantly with age, changes in Peak VO\textsubscript{2}, T-Chol, triglyceride, LDL-C, HDL-C, non-HDL, ubiquinol, fasting blood glucose and HbA1c (Figure 3B–D, Table 3).

Comparison of Arterial Wall Stiffness and Change in Plasma Basophil in Rosuvastatin and Atorvastatin Groups

Finally, the test parameters were analyzed according to the type of statin used for treatment. The baseline baPWV (atorvastatin: 1729±635, rosuvastatin: 1766±636 cm/s, p = 0.789) and plasma basophil count (atorvastatin: 44±34, rosuvastatin: 40±30 cells/μL, p = 0.703) were not significantly different between the two groups. Rosuvastatin combined with regular exercise significantly decreased baPWV (Figure 4A) and basophil count (Figure 4B), but atorvastatin did not. Changes in baPWV correlated significantly with plasma basophil count in the rosuvastatin group (Figure 4D), but not in the atorvastatin group (Figure 4C).

Discussion

The major finding of our study is that the combination of statins (atorvastatin or rosuvastatin) and regular exercise significantly ameliorated arterial wall stiffness, which correlated with reduced basophil count in patients with CAD.

Increased arterial wall stiffness is a risk factor for cardiovascular events through increased cardiac afterload, impaired coronary blood flow, atherogenesis and microangiopathies [5]. Several

![Figure 2. Association Between Arterial Wall Stiffness and Each Plasma Leukocyte.](image-url)

Correlations between changes in brachial and ankle pulse wave velocity (baPWV) and (A) basophil count, (B) total leukocyte count, (C) neutrophil count, (D) lymphocyte count, (E) monocyte count, (F) eosinophil count.

doi:10.1371/journal.pone.0041369.g002
methods, such as flow-mediated vasodilation and PWV, are used to assess vascular function. PWV is a useful method to assess increased arterial wall stiffness. Reduction in PWV levels is potentially beneficial in the management of patients with CAD. Advanced age, glucose intolerance, lipid profile abnormalities, high CRP, and oxidative stress correlate with increased arterial wall stiffness [9–12], however we could not find in the present study any significant association between the above factors and changes in arterial wall stiffness assessed by PWV. Aerobic exercise in patients with CAD plays a beneficial role in secondary prevention by improvement of cardiopulmonary function, modulation of various cardiometabolic risk factors [1,13], and amelioration of arterial wall stiffness [14]. Statins, such as pravastatin, have been reported to improve arterial wall stiffness in association with a reduction in leukocyte subtypes such as monocytes [15]. However, the effect of statins on arterial wall stiffness was not confirmed in a recent meta-analysis study [16]. Our study confirmed the clinical effectiveness of the combination therapy of statin and exercise in reducing increased arterial wall stiffness in CAD patients.

Basophils represent less than 1% of the total leukocyte count in peripheral blood and are considered possibly redundant relative to mast cells in tissues. New information on their function and clinical significance has emerged recently. T helper type 1 (Th1) lymphocytes produce interferon-γ, interleukin (IL)-2 and tumor necrosis factor-α, which are associated with cell-mediated immunity, while T helper type 2 (Th2) lymphocytes produce IL-4, 5 and 10, which are associated with humoral immunity and antibody production. Recent studies have reported the importance of basophils in the initiation of Th2 responses by secreting IL-4, which is involved in the development of immunological abnormalities, such as allergic and autoimmune disorders [17].

![Figure 3. Association Between Arterial Wall Stiffness and Other Parameters.](image)

**Table 3. Correlations Between Changes in PWV and Other Parameters.**

| Parameter                          | r    | p value |
|------------------------------------|------|---------|
| Age (years)                        | -0.060 | 0.763   |
| Peak Oxygen Uptake                 | 0.270 | 0.165   |
| Total Cholesterol (mg/mL)          | -0.099 | 0.616   |
| Triglyceride (mg/mL)               | 0.214 | 0.274   |
| Non-High-Density Lipoprotein       | -0.101 | 0.608   |
| Cholesterol (mg/mL)                |      |         |
| Ubiquinol (nmol/L)                 | -0.236 | 0.226   |
| Fasting Blood Glucose (mg/dL)      | -0.085 | 0.669   |

doi:10.1371/journal.pone.0041369.t003
However, further details are needed about the potential involvement of basophils and basophil-mediated immune response in cardiovascular diseases. In the early and mid-1990s, the importance of mast cells, but not basophils, in the pathogenesis of atherosclerosis and vascular diseases was reported [18,19]. Both the Th1 response and the Th2 response are important in the process of atherosclerogenesis [20]. Furthermore, Schonbeck et al. [21] have shown that Th2 cytokines and Th2 characteristic response predominate in human aortic aneurysms. Recent reports also described the critical role of adventitial mast cells in the progression of atherosclerosis and aortic aneurysm [22]. Libby et al. [23,24] provided new data on the importance of mast cells in atherosclerosis. In a manner similar to mast cells in the atherosclerotic intima and adventitia, the increased circulating basophil-mediated Th2-immune response could play a role in the progression of atherosclerotic changes through the initiation of Th2, similar also to the circulating monocytes [15,25] [26]. On the other hand, aerobic exercise is also reported to reduce the expression of Th2 cytokines in a mouse model [27]. Several groups have reported the inhibition of Th1 responses by statins [28]. Therefore, the combination therapy of aerobic exercise and statins could improve the imbalance in Th1/2 responses in atheroscle-
rotic diseases by decreasing the number of basophils in peripheral blood. The present study is the first report that demonstrated: (1) significant reduction in arterial wall stiffness and plasma basophil count after statin treatment combined with regular exercise intervention, and (2) a significant association between changes in arterial wall stiffness and plasma basophil count.

We investigated previously the use of atorvastatin and rosuvastatin combined with regular exercise on HDL-C in Japanese CAD patients [4]. Surprisingly, we found significant differences between the two statins; indicating the superiority of rosuvastatin, compared to atorvastatin, with exercise in increasing HDL-C and preservation of ubiquinol, an anti-oxidant effect. In the present study, we found (1) a significant decrease in arterial wall stiffness and plasma basophil count, and (2) a significant positive correlation between arterial wall stiffness and changes in plasma basophil count in the rosuvastatin group, but not in the atorvastatin group. It is probable that rosuvastatin inhibits the Th2-response by reducing basophil count, in addition to inhibiting the Th1 cytokines, and that the combination of exercise and rosuvastatin, compared to atorvastatin, has an anti-inflammatory and immuno-agonist properties in atherosclerotic lesions. Admittedly, the effect of rosuvastatin on the Th1/Th2 responses was not examined in detail in the present study. It has been shown that an increase in HDL-C and suppressed oxidative stress levels have a key role in the regression of the atherosclerotic changes [29,30]. The increased HDL-C and the preserved levels of anti-oxidant molecule in rosuvastatin group, but not in atorvastatin, could be another possible mechanism for the amelioration of the arterial wall stiffness [4]. Little is known about why the difference existed according to two types of statin used, hydrophilic or lipophlic, on atherosclerosis. Several papers have reported the different effect of rosuvastatin and atorvastatin on atherosclerotic changes; ie, the greater decrease in coronary atheroma volume was observed in the rosuvastatin group, but not in atorvastatin group. They have reported the Th1 cytokines, and that the combination therapy correlated with reduction in circulating basophils in CAD patients with arterial wall stiffness.

Acknowledgments
The authors thank Mari Hamada (Registered instructor of cardiac rehabilitation), Ayako Satoda (Cardiopulmonary exercise test technician), Tomoko Horikawa (Medical sonographer), Yuko Sakamoto (Medical technologist), Motoki Kamura and Yukari Fukushima (Pharmacists), Kyoko Hiri and Manabu Kinoshita (Clinical Research Center staff), and Haruna Toyama, for the excellent support during the study.

Author Contributions
Conceived and designed the experiments: KT SS H. Oka H. Ogawa. Performed the experiments: KT H. Oka YI. Analyzed the data: KT SS. Contributed reagents/materials/analysis tools: KT SS H. Oka HS TT ST HJ. Wrote the paper: KT SS.

References
1. Toyama K, Sugiyama S, Oka H, Sumida H, Ogawa H (2010) Exercise therapy correlates with improving renal function through modifying lipid metabolism in patients with cardiovascular disease and chronic kidney disease. J Cardiof 56: 142–146.
2. Geel K, Lemon RJ, Tilbury RT, Squires RW, Thomas RJ (2011) Impact of cardiac rehabilitation on mortality and cardiovascular events after percutaneous coronary intervention in the community. Circulation 123: 2344–2352.
3. LaRosa JC, Grundy SM, Waters DD, Shear C, Barter P, et al. (2005) Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 352: 1425–1435.
4. Toyama K, Sugiyama S, Oka H, Iwasaki Y, Sumida H, et al. (2011) Rosuvastatin combined with regular exercise preserves coronary Q10 levels associated with a significant increase in high-density lipoprotein cholesterol in patients with coronary artery disease. Atherosclerosis 217: 158–164.
5. Tomiyama H, Yamashina A (2010) Non-invasive vascular function tests: their pathophysiologival background and clinical application. Circ J 74: 24–33.
6. Pietri P, Vysoulis G, Vlachopoulos C, Zervoudaki A, Giadernios T, et al. (2006) Relationship between low-grade inflammation and arterial stiffness in patients with essential hypertension. J Hyper 24: 2231–2233.
7. JAS (2007) [Japan Atherosclerosis Society (JAS) guidelines for prevention of atherosclerotic cardiovascular diseases]. J Atheroscler Thromb: 5–57.
8. Imanishi R, Seto S, Toda G, Yoshida M, Ohtsuru A, et al. (2004) High brachial-ankle pulse wave velocity is an independent predictor of the presence of coronary artery disease in men. Hypertens Res 27: 71–78.
9. Vysoulis G, Pietri P, Vlachopoulos C, Alexopoulos N, Kyvelos SM, et al. (2012) Early adverse effect of abnormal glucose metabolism on arterial stiffness in drug naive hypertensive patients. Dia Vasc Di Res 9: 18–24.
10. Hong L, Matsubara H, Hijikata H, Kamazaki S, et al. (2008) Rosuvastatin improves arterial stiffness in patients with coronary artery disease and hyperlipidemia: a 5-year follow-up study. Circ J 72: 722–728.
11. Wang F, Ye P, Luo L, Xiao W, Qi L, et al. (2011) Association of serum lipids with arterial stiffness in a population-based study in Beijing. Eur J Clin Invest 41: 929–936.
12. Wilkinson IB, Franklin SS, Cockcroft JR (2004) Nitric oxide and the regulation of large artery stiffness: from physiology to pharmacology. Hypertension 44: 112–116.
13. Taylor RS, Brown A, Ebrahim S, Jolliffe J, Neurani H, et al. (2004) Exercise-based rehabilitation for patients with coronary heart disease: systematic review and meta-analysis of randomized controlled trials. Am J Med 116: 682–692.
14. Michaelides AP, Souls D, Antoniades C, Antonopoulou AS, Miliou A, et al. (2011) Exercise duration as a determinant of vascular function and antioxidant balance in patients with coronary artery disease. Heart 97: 832–837.
15. Tani S, Nagao K, Anazawa T, Kawamura H, Furuya S, et al. (2009) Association of leukocyte subtype counts with coronary atherosclerotic regression following pravastatin treatment. Am J Cardiol 104: 464–469.
16. Rizos EC, Agouridis AP, Eliaf MS (2010) The effect of statin therapy on arterial stiffness by measuring pulse wave velocity: a systematic review. Curr Vasc Pharmacol 8: 638–644.
17. Karasuyama H, Mukai K, Ohata K, Tsujimura Y, Wada T (2011) Nonredundant roles of basophils in immunity. Annu Rev Immunol 29: 45–69.
18. Dvorak AM (1997) New aspects of mast cell biology. Int Arch Allergy Immunol 114: 1–9.
19. Metzler B, Xu Q (1997) The role of mast cells in atherosclerosis. Int Arch Allergy Immunol 114: 10–14.
20. Davenport P, Tipping PG (2003) The role of interleukin-4 and interleukin-12 in the progression of atherosclerosis in apolipoprotein E-deficient mice. Am J Pathol 163: 1117–1125.
21. Shinmizu K, Shichiri M, Libby P, Lee RT, Mitchell RN (2004) Th2-predominant inflammation and blockade of IFN-gamma signaling induce aneurysms in allografted aorta. J Clin Invest 114: 300–308.
22. Tsuruda T, Kato J, Hatakeyama K, Kojima K, Yano M, et al. (2008) Adventitial mast cells contribute to pathogenesis in the progression of abdominal aortic aneurysm. Circ Res 102: 1368–1377.
23. Libby P, Shi GP (2007) Mast cells as mediators and modulators of atherogenesis. Circulation 115: 2471–2473.
24. Libby P, Radler PM, Hansen GK (2009) Inflammation in atherosclerosis: from pathophysiology to practice. J Am Coll Cardiol 54: 2129–2138.
25. Salonen R, Salonen JT (1990) Progression of carotid atherosclerosis and its determinants: a population-based ultrasonography study. Atherosclerosis 81: 33–40.
26. Ross R (1999) Atherosclerosis--an inflammatory disease. N Engl J Med 340: 115–126.
27. Vieira RP, Claudino RG, Duarte AC, Santos AB, Perini A, et al. (2007) Aerobic exercise decreases chronic allergic lung inflammation and airway remodeling in mice. Am J Respir Crit Care Med 176: 871–877.
28. Cheng X, Ding Y, Xia C, Tang T, Yu X, et al. (2009) Atorvastatin modulates Th1/Th2 response in patients with chronic heart failure. J Card Fail 15: 158–162.
29. Nickolls SJ, Tsuuru EM, Breman DM, Tardif JC, Nissen SE (2008) Cholesteryl ester transfer protein inhibition, high-density lipoprotein raising, and progression of coronary atherosclerosis: insights from ILLUSTRATE (Investigation of Lipid Level Management Using Coronary Ultrasound to Assess Reduction of Atherosclerosis by CETP Inhibition and HDL Elevation). Circulation 118: 2506–2514.
30. Fearon IM, Faux SP (2009) Oxidative stress and cardiovascular disease: novel tools give (free) radical insight. J Mol Cell Cardiol 47: 372–381.
31. Lee CW, Kang SJ, Ahn JM, Song HG, Lee JY, et al. (2012) Comparison of Effects of Atorvastatin (20 mg) Versus Rosuvastatin (10 mg) Therapy on Mild Coronary Atherosclerotic Plaques (from the ARTMAP Trial). Am J Cardiol 109: 1700–1704.
32. Rawlings R, Nohria A, Liu PY, Donnelly J, Creager MA, et al. (2009) Comparison of effects of rouvastatin (10 mg) versus atorvastatin (40 mg) on rho kinase activity in caucasian men with a previous atherosclerotic event. Am J Cardiol 103: 437–441.
33. Yamashina A, Tomiyama H, Takeda K, Tsuda H, Arai T, et al. (2002) Validity, reproducibility, and clinical significance of noninvasive brachial-ankle pulse wave velocity measurement. Hypertens Res 25: 359–364.
34. Anundsen EK, Henriksson CE, Holthe MR, Urdal P (2012) Is the blood basophil count sufficiently precise, accurate, and specific?: three automated hematology instruments and flow cytometry compared. Am J Clin Pathol 137: 86–92.